[Complications of immunosuppression]

Area of Science:

• Pharmacology
• Immunology
• Nephrology

Background:

• Several novel immunosuppressive agents are nearing availability, including Cyclosporin G, FK506, Rapamycin, and various monoclonal antibodies.
• These new drugs offer potential advancements in immunosuppression but also present a complex landscape of potential adverse effects.

Purpose of the Study:

• To review and classify the anticipated side effects of emerging immunosuppressive substances.
• To highlight the specific concerns regarding nephrotoxicity associated with Cyclosporin A and its management.
• To address the challenges in evaluating the safety profiles of a growing number of immunosuppressive drugs.

Main Methods:

• Literature review of new immunosuppressive drugs and their known or predicted side effects.
• Classification of side effects into drug-specific and over-immunosuppression categories.
• Detailed examination of Cyclosporin A nephrotoxicity and preventative strategies.

Main Results:

• Anticipated side effects are categorized as either relative drug-specific or unspecific effects stemming from over-immunosuppression, such as infections and malignancies.
• Nephrotoxicity is a significant concern, particularly with Cyclosporin A, necessitating clear guidelines for prevention.
• The increasing number of available agents complicates the comprehensive evaluation of individual drug safety.

Conclusions:

• The proliferation of new immunosuppressive drugs necessitates a thorough and cautious approach to side effect evaluation.
• Effective management strategies are required to mitigate risks associated with these potent medications.
• Ongoing research and vigilant monitoring are essential to ensure patient safety in the era of advanced immunosuppression.